Montanova Capital, LLC has filed an amendment to its Schedule 13G, detailing its ownership stake in Aura Biosciences, Inc. This filing, dated November 13, 2026, reveals that Montanova holds 2,973,971 shares of Aura, representing approximately 2.9% of the company's common stock. The update is significant as it underscores Montanova's ongoing investment strategy within the life sciences sector.

Aura Biosciences, Inc. operates in the biological products industry, specifically focusing on products that do not include diagnostic substances. The company, incorporated in Delaware, is based in Boston, Massachusetts, and is listed under the Central Index Key number 0001501796.

According to the filing, Montanova Capital's stake is shared with Averill Master Fund, Ltd., which owns 2,535,780 shares, or 2.4% of Aura's common stock. The filing states, "None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock." This indicates a collaborative investment approach among the entities involved.

The filing also mentions that Aaron Cowen has shared voting and dispositive power over the same number of shares as Montanova, further emphasizing the interconnected nature of these holdings. The filing does not indicate any immediate plans for further action or changes in ownership structure.

As Montanova Capital continues to build its portfolio in the life sciences sector, its actions may influence market dynamics and competitive strategies among other firms in the industry. The filing does not specify what happens next, leaving investors and analysts to speculate on the potential implications of this significant stake.